Ocular Therapeutix, Inc. s in-depth stock price analysis indicates that the stock price has dropped -22.55% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 32.65% . Looking at the past 52 week period, the stock price is up at 51.16% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Ocular Therapeutix, Inc. has a negative value of -13.35 compared to overall market performance. Ocular Therapeutix, Inc. (NASDAQ:OCUL) has climbed 22.82% in the past week and advanced 4.45% in the last 4 weeks. In the past week, the company has outperformed the S&P 500 by 21.83% and the outperformance has advanced to 2.58% for the last 4 weeks period.
Ocular Therapeutix, Inc. (NASDAQ:OCUL) : On Friday heightened volatility was witnessed in Ocular Therapeutix, Inc. (NASDAQ:OCUL) which led to swings in the share price. The stock opened for trading at $7.77 and hit $8.91 on the upside , eventually ending the session at $8.45, with a gain of 17.69% or 1.27 points. The heightened volatility saw the trading volume jump to 4,317,065 shares. The 52-week high of the share price is $14.5 and the company has a market cap of $213 million. The 52-week low of the share price is at $4.04 .
Ocular Therapeutix Inc Last issued its quarterly earnings results on Nov 9, 2016. The company reported $-0.39 EPS for the quarter, beating the analyst consensus estimate by $ 0.11. Analyst had a consensus of $-0.50.Analysts expectations of $ .47.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Ocular Therapeutix Inc was Initiated by Cantor Fitzgerald on Feb 10, 2017 to Overweight, Price Target of the shares are set at $35.Company shares were Reiterated by RBC Capital Mkts on Nov 15, 2016 to Outperform, Raises Price Target to $ 32 from a previous price target of $30 .
Company has reported several Insider transactions to the SEC, on Dec 16, 2016, Amarpreet Sawhney (CEO) purchased 45,300 shares at 7.85 per share price.On Sep 17, 2015, James Fortune (Chief Operating Officer) sold 9,470 shares at 17.16 per share price.On Jun 15, 2015, Charles M Warden (director 10% owner) sold 320,000 shares at 22.00 per share price.
Ocular Therapeutix, Inc. is a biopharmaceutical company. It is focused on the development and commercialization of ophthalmic therapeutic products using its proprietary hydrogel technology to address unmet or underserved needs in ophthalmology. The Company develops and markets eye care products. Ocular Therapeutix, Inc. is headquartered in Bedford, Massachusetts.